

Quotient Limited Launches Scientific Advisory Board and Research Programs

- MosaiQ virtual Scientific Advisory Board (SAB) was attended this week by eight Key Opinion Leaders (KOLs) from the US and various European countries
- Quotient's focus is to strengthen MosaiQ scientific and medical evidence through the Innovator's Circle and Investigator Initiated research programs
- Quotient is initiating studies to demonstrate operational value and workflow benefits within the laboratory

JERSEY, Channel Islands, January 26th, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today provided a Scientific Advisory Board and Research Program update. Quotient's Senior Management and Research and Development teams gathered with eight Transfusion Medicine KOLs from the US and Europe to highlight recent advances and future applications of the MosaiQ system. The Scientific and Medical Affairs Office has launched two new programs, the Innovator's Circle and an Investigator Initiated Research Program that will engage multiple global sites. Both are designed to foster developmental excellence in clinical diagnostics supported by independent and collaborative research to demonstrate the operational, scientific, and clinical value of MosaiQ's innovative technology.

"It was a pleasure meeting with key global investigators to accelerate the adoption of our disruptive technology by enabling independent scientific evidence that supports the technical and clinical use of MosaiQ. Through scientific collaborations with KOLs and Transfusion Medicine Centers, we are committed to demonstrating laboratory efficiency and patient centered outcomes," said Dr. Christine Ginocchio, Chief Scientific & Medical Officer of Quotient.

"I am excited to collaborate with Dr. Ginocchio in building the MosaiQ laboratory and clinical value. This will support our goal to partner with our customers in improving patient care," said Manuel O. Méndez, Chief Executive Officer of Quotient.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.



Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company's MosaiQ technology to infectious disease diagnostics), current estimates of third quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations, ir@quotientbd.com; +41 22 545 52 26